Lisdexamfetamine Dimesylate Capsules Solicitation

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-26-R-0004

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents3
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued a solicitation (Procurement Identifier: SPE2D2-26-R-0004) for the supply of Lisdexamfetamine Dimesylate Capsules. This procurement falls under NAICS Code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code 6505, indicating a focus on pharmaceuticals. The primary objective of this solicitation is to secure a reliable source for Lisdexamfetamine Dimesylate Capsules, a medication commonly used in the treatment of attention deficit hyperactivity disorder (ADHD) and certain other medical conditions. The intended outcome is to ensure the consistent availability of this pharmaceutical product to meet the needs of military personnel and other authorized recipients supported by DLA Troop Support. Amendment 0002 to the solicitation has extended the deadline for offer submissions, with all proposals now due by July 28, 2026, at 19:07. This extension provides additional time for interested and qualified contractors to prepare and submit comprehensive offers in response to the agency’s requirements. Key requirements and expected deliverables for this procurement include the manufacturing and timely delivery of Lisdexamfetamine Dimesylate Capsules in accordance with all applicable federal regulations and quality standards. Contractors must demonstrate the capability to produce pharmaceutical-grade products that meet the specifications outlined in the solicitation documents. While the specific quantities, packaging, and delivery schedules are not detailed in the provided notice, interested parties are encouraged to review the three attachments available on the SAM.gov opportunity page for further technical and contractual requirements. The contracting entity for this opportunity is DLA Troop Support, a federal office within the Defense Logistics Agency, which is responsible for the procurement and supply of medical and pharmaceutical products to the Department of Defense. The primary point of contact for this solicitation is Courtney Hunter ([email protected], 445-737-3585), with Jason Wray ([email protected], 445-737-6304) listed as the secondary contact. These individuals can provide additional information and clarification regarding the solicitation process. This is a formal solicitation, and the notice is currently active. Contractors interested in pursuing this opportunity should ensure they are registered in SAM.gov and review all solicitation documents and attachments for detailed instructions and requirements. No specific set-aside requirements or special considerations are mentioned in the provided information; therefore, all qualified manufacturers and suppliers of pharmaceutical preparations are encouraged to consider this opportunity. For further details, including access to solicitation attachments and updates, contractors should refer to the official notice on SAM.gov at the following URL: https://sam.gov/opp/90b6e4455c0040dcb1f0c93c19e56ae5/view. This procurement represents a significant opportunity for pharmaceutical manufacturers with the capability to supply high-quality Lisdexamfetamine Dimesylate Capsules in support of the Department of Defense’s ongoing medical supply needs.